Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk

NCT04473924 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04473924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04473924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2022
Completion date
May 31, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infection, transplant;failure,kidney